U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C18H21N5O2.C7H6O2
Molecular Weight 461.5139
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ALOGLIPTIN BENZOATE

SMILES

Cn1c(=O)cc(N2CCC[C@]([H])(C2)N)n(Cc3ccccc3C#N)c1=O.c1ccc(cc1)C(=O)O

InChI

InChIKey=KEJICOXJTRHYAK-XFULWGLBSA-N
InChI=1S/C18H21N5O2.C7H6O2/c1-21-17(24)9-16(22-8-4-7-15(20)12-22)23(18(21)25)11-14-6-3-2-5-13(14)10-19;8-7(9)6-4-2-1-3-5-6/h2-3,5-6,9,15H,4,7-8,11-12,20H2,1H3;1-5H,(H,8,9)/t15-;/m1./s1

HIDE SMILES / InChI

Molecular Formula C18H21N5O2
Molecular Weight 339.3923
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula C7H6O2
Molecular Weight 122.1216
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: description was created based on several sources, including https://www.takeda.com/news/2013/20130924_5997.html; http://www.ncbi.nlm.nih.gov/pubmed/22651127; http://www.ncbi.nlm.nih.gov/pubmed/17441705

Alogliptin (trade name Nesina in the US and Vipidia in Europe) is an orally administered anti-diabetic drug in the DPP-4 inhibitor class, discovered by Takeda Pharmaceutical Company's wholly owned subsidiary, Takeda San Diego, Inc. (former Syrrx) which was acquired by Takeda in 2005. Alogliptin does not decrease the risk of heart attack and stroke. Like other members of the gliptin class, it causes little or no weight gain, exhibits relatively little risk of causing hypoglycemia, and exhibits relatively modest glucose-lowering activity. Alogliptin and other gliptins are commonly used in combination with metformin in patients whose diabetes cannot adequately be controlled with metformin alone.

CNS Activity

Curator's Comment:: Alogliptin is unlikely to have untoward pharmacologic activity in the central nervous system (CNS). Although alogliptin inhibited naloxone binding at nonselective opioid receptors in vitro in the rat cerebral cortex, it did not show any binding affinity for human receptors typically associated with abuse potential (human recombinant opiate receptors).

Originator

Curator's Comment:: Alogliptin was discovered by Takeda’s wholly owned subsidiary, Takeda San Diego, Inc. # Takeda San Diego, Inc.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P27487
Gene ID: 1803.0
Gene Symbol: DPP4
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Secondary
NESINA

Approved Use

Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitation of Use: Not for treatment of type 1 diabetes or diabetic ketoacidosis.

Launch Date

1.35907194E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
165 ng/mL
25 mg 1 times / day steady-state, oral
dose: 25 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
[NO STEREO] ALOGLIPTIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
154.83 ng/mL
25 mg 1 times / day multiple, oral
dose: 25 mg
route of administration: oral
experiment type: multiple
co-administered:
ALOGLIPTIN plasma
Homo sapiens
population: healthy
age: Adults
sex:
food status:
335.36 ng/mL
50 mg 1 times / day multiple, oral
dose: 50 mg
route of administration: oral
experiment type: multiple
co-administered:
ALOGLIPTIN plasma
Homo sapiens
population: healthy
age: Adults
sex:
food status:
75.38 ng/mL
12.5 mg 1 times / day multiple, oral
dose: 12.5 mg
route of administration: oral
experiment type: multiple
co-administered:
ALOGLIPTIN plasma
Homo sapiens
population: healthy
age: Adults
sex:
food status:
114.08 ng/mL
25 mg single, oral
dose: 25 mg
route of administration: oral
experiment type: single
co-administered:
ALOGLIPTIN plasma
Homo sapiens
population: healthy
age: Adults
sex:
food status:
246 ng/mL
50 mg single, oral
dose: 50 mg
route of administration: oral
experiment type: single
co-administered:
ALOGLIPTIN plasma
Homo sapiens
population: healthy
age: Adults
sex:
food status:
55.28 ng/mL
12.5 mg single, oral
dose: 12.5 mg
route of administration: oral
experiment type: single
co-administered:
ALOGLIPTIN plasma
Homo sapiens
population: healthy
age: Adults
sex:
food status:
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1511 ng × h/mL
25 mg 1 times / day steady-state, oral
dose: 25 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
[NO STEREO] ALOGLIPTIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
1174.76 ng*h/mL
25 mg single, oral
dose: 25 mg
route of administration: oral
experiment type: single
co-administered:
ALOGLIPTIN plasma
Homo sapiens
population: healthy
age: Adults
sex:
food status:
1625.58 ng*h/mL
25 mg 1 times / day multiple, oral
dose: 25 mg
route of administration: oral
experiment type: multiple
co-administered:
ALOGLIPTIN plasma
Homo sapiens
population: healthy
age: Adults
sex:
food status:
2488.48 ng*h/mL
50 mg single, oral
dose: 50 mg
route of administration: oral
experiment type: single
co-administered:
ALOGLIPTIN plasma
Homo sapiens
population: healthy
age: Adults
sex:
food status:
3389.21 ng*h/mL
50 mg 1 times / day multiple, oral
dose: 50 mg
route of administration: oral
experiment type: multiple
co-administered:
ALOGLIPTIN plasma
Homo sapiens
population: healthy
age: Adults
sex:
food status:
601.65 ng*h/mL
12.5 mg single, oral
dose: 12.5 mg
route of administration: oral
experiment type: single
co-administered:
ALOGLIPTIN plasma
Homo sapiens
population: healthy
age: Adults
sex:
food status:
842.17 ng*h/mL
12.5 mg 1 times / day multiple, oral
dose: 12.5 mg
route of administration: oral
experiment type: multiple
co-administered:
ALOGLIPTIN plasma
Homo sapiens
population: healthy
age: Adults
sex:
food status:
1674.87999999999 ng*h/mL
25 mg single, oral
dose: 25 mg
route of administration: oral
experiment type: single
co-administered:
ALOGLIPTIN plasma
Homo sapiens
population: healthy
age: Adults
sex:
food status:
3306.68 ng*h/mL
50 mg single, oral
dose: 50 mg
route of administration: oral
experiment type: single
co-administered:
ALOGLIPTIN plasma
Homo sapiens
population: healthy
age: Adults
sex:
food status:
895.28 ng*h/mL
12.5 mg single, oral
dose: 12.5 mg
route of administration: oral
experiment type: single
co-administered:
ALOGLIPTIN plasma
Homo sapiens
population: healthy
age: Adults
sex:
food status:
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
16.9 h
25 mg 1 times / day steady-state, oral
dose: 25 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
[NO STEREO] ALOGLIPTIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
21 h
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
[NO STEREO] ALOGLIPTIN plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
20.67 h
12.5 mg single, oral
dose: 12.5 mg
route of administration: oral
experiment type: single
co-administered:
ALOGLIPTIN plasma
Homo sapiens
population: healthy
age: Adults
sex:
food status:
19.45 h
25 mg single, oral
dose: 25 mg
route of administration: oral
experiment type: single
co-administered:
ALOGLIPTIN plasma
Homo sapiens
population: healthy
age: Adults
sex:
food status:
17 h
50 mg single, oral
dose: 50 mg
route of administration: oral
experiment type: single
co-administered:
ALOGLIPTIN plasma
Homo sapiens
population: healthy
age: Adults
sex:
food status:
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
80%
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
[NO STEREO] ALOGLIPTIN plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
800 mg single, oral
Highest studied dose
Dose: 800 mg
Route: oral
Route: single
Dose: 800 mg
Sources:
healthy, 26.6 years (range: 18-55 years)
n = 5
Health Status: healthy
Age Group: 26.6 years (range: 18-55 years)
Sex: M
Population Size: 5
Sources:
400 mg 1 times / day steady, oral
Highest studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 55.6 years (range: 18 - 75 years)
n = 16
Health Status: unhealthy
Condition: type 2 diabetes
Age Group: 55.6 years (range: 18 - 75 years)
Sex: M+F
Population Size: 16
Sources:
Other AEs: Headache, Dizziness...
Other AEs:
Headache (6 patients)
Dizziness (4 patients)
Constipation (3 patients)
Sources:
25 mg 1 times / day steady, oral
Recommended
Dose: 25 mg, 1 times / day
Route: oral
Route: steady
Dose: 25 mg, 1 times / day
Sources: Page: p. 48
unhealthy, adult
n = 6626
Health Status: unhealthy
Age Group: adult
Population Size: 6626
Sources: Page: p. 48
Disc. AE: Acute myocardial infarction, Angina unstable...
AEs leading to
discontinuation/dose reduction:
Acute myocardial infarction (8 patients)
Angina unstable (2 patients)
Myocardial infarction (12 patients)
Abdominal pain (2 patients)
Diarrhea (1 patient)
Nausea (3 patients)
Edema peripheral (4 patients)
Blood creatinine increased (6 patients)
Creatinine renal clearance abnormal (3 patients)
Creatinine renal clearance decreased (22 patients)
Lipase increased (10 patients)
Hyperglycemia (3 patients)
Dizziness (4 patients)
Headache (2 patients)
Renal impairment (13 patients)
Rash (2 patients)
Rash pruritic (3 patients)
Sources: Page: p. 48
AEs

AEs

AESignificanceDosePopulation
Constipation 3 patients
400 mg 1 times / day steady, oral
Highest studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 55.6 years (range: 18 - 75 years)
n = 16
Health Status: unhealthy
Condition: type 2 diabetes
Age Group: 55.6 years (range: 18 - 75 years)
Sex: M+F
Population Size: 16
Sources:
Dizziness 4 patients
400 mg 1 times / day steady, oral
Highest studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 55.6 years (range: 18 - 75 years)
n = 16
Health Status: unhealthy
Condition: type 2 diabetes
Age Group: 55.6 years (range: 18 - 75 years)
Sex: M+F
Population Size: 16
Sources:
Headache 6 patients
400 mg 1 times / day steady, oral
Highest studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 55.6 years (range: 18 - 75 years)
n = 16
Health Status: unhealthy
Condition: type 2 diabetes
Age Group: 55.6 years (range: 18 - 75 years)
Sex: M+F
Population Size: 16
Sources:
Diarrhea 1 patient
Disc. AE
25 mg 1 times / day steady, oral
Recommended
Dose: 25 mg, 1 times / day
Route: oral
Route: steady
Dose: 25 mg, 1 times / day
Sources: Page: p. 48
unhealthy, adult
n = 6626
Health Status: unhealthy
Age Group: adult
Population Size: 6626
Sources: Page: p. 48
Lipase increased 10 patients
Disc. AE
25 mg 1 times / day steady, oral
Recommended
Dose: 25 mg, 1 times / day
Route: oral
Route: steady
Dose: 25 mg, 1 times / day
Sources: Page: p. 48
unhealthy, adult
n = 6626
Health Status: unhealthy
Age Group: adult
Population Size: 6626
Sources: Page: p. 48
Myocardial infarction 12 patients
Disc. AE
25 mg 1 times / day steady, oral
Recommended
Dose: 25 mg, 1 times / day
Route: oral
Route: steady
Dose: 25 mg, 1 times / day
Sources: Page: p. 48
unhealthy, adult
n = 6626
Health Status: unhealthy
Age Group: adult
Population Size: 6626
Sources: Page: p. 48
Renal impairment 13 patients
Disc. AE
25 mg 1 times / day steady, oral
Recommended
Dose: 25 mg, 1 times / day
Route: oral
Route: steady
Dose: 25 mg, 1 times / day
Sources: Page: p. 48
unhealthy, adult
n = 6626
Health Status: unhealthy
Age Group: adult
Population Size: 6626
Sources: Page: p. 48
Abdominal pain 2 patients
Disc. AE
25 mg 1 times / day steady, oral
Recommended
Dose: 25 mg, 1 times / day
Route: oral
Route: steady
Dose: 25 mg, 1 times / day
Sources: Page: p. 48
unhealthy, adult
n = 6626
Health Status: unhealthy
Age Group: adult
Population Size: 6626
Sources: Page: p. 48
Angina unstable 2 patients
Disc. AE
25 mg 1 times / day steady, oral
Recommended
Dose: 25 mg, 1 times / day
Route: oral
Route: steady
Dose: 25 mg, 1 times / day
Sources: Page: p. 48
unhealthy, adult
n = 6626
Health Status: unhealthy
Age Group: adult
Population Size: 6626
Sources: Page: p. 48
Headache 2 patients
Disc. AE
25 mg 1 times / day steady, oral
Recommended
Dose: 25 mg, 1 times / day
Route: oral
Route: steady
Dose: 25 mg, 1 times / day
Sources: Page: p. 48
unhealthy, adult
n = 6626
Health Status: unhealthy
Age Group: adult
Population Size: 6626
Sources: Page: p. 48
Rash 2 patients
Disc. AE
25 mg 1 times / day steady, oral
Recommended
Dose: 25 mg, 1 times / day
Route: oral
Route: steady
Dose: 25 mg, 1 times / day
Sources: Page: p. 48
unhealthy, adult
n = 6626
Health Status: unhealthy
Age Group: adult
Population Size: 6626
Sources: Page: p. 48
Creatinine renal clearance decreased 22 patients
Disc. AE
25 mg 1 times / day steady, oral
Recommended
Dose: 25 mg, 1 times / day
Route: oral
Route: steady
Dose: 25 mg, 1 times / day
Sources: Page: p. 48
unhealthy, adult
n = 6626
Health Status: unhealthy
Age Group: adult
Population Size: 6626
Sources: Page: p. 48
Creatinine renal clearance abnormal 3 patients
Disc. AE
25 mg 1 times / day steady, oral
Recommended
Dose: 25 mg, 1 times / day
Route: oral
Route: steady
Dose: 25 mg, 1 times / day
Sources: Page: p. 48
unhealthy, adult
n = 6626
Health Status: unhealthy
Age Group: adult
Population Size: 6626
Sources: Page: p. 48
Hyperglycemia 3 patients
Disc. AE
25 mg 1 times / day steady, oral
Recommended
Dose: 25 mg, 1 times / day
Route: oral
Route: steady
Dose: 25 mg, 1 times / day
Sources: Page: p. 48
unhealthy, adult
n = 6626
Health Status: unhealthy
Age Group: adult
Population Size: 6626
Sources: Page: p. 48
Nausea 3 patients
Disc. AE
25 mg 1 times / day steady, oral
Recommended
Dose: 25 mg, 1 times / day
Route: oral
Route: steady
Dose: 25 mg, 1 times / day
Sources: Page: p. 48
unhealthy, adult
n = 6626
Health Status: unhealthy
Age Group: adult
Population Size: 6626
Sources: Page: p. 48
Rash pruritic 3 patients
Disc. AE
25 mg 1 times / day steady, oral
Recommended
Dose: 25 mg, 1 times / day
Route: oral
Route: steady
Dose: 25 mg, 1 times / day
Sources: Page: p. 48
unhealthy, adult
n = 6626
Health Status: unhealthy
Age Group: adult
Population Size: 6626
Sources: Page: p. 48
Dizziness 4 patients
Disc. AE
25 mg 1 times / day steady, oral
Recommended
Dose: 25 mg, 1 times / day
Route: oral
Route: steady
Dose: 25 mg, 1 times / day
Sources: Page: p. 48
unhealthy, adult
n = 6626
Health Status: unhealthy
Age Group: adult
Population Size: 6626
Sources: Page: p. 48
Edema peripheral 4 patients
Disc. AE
25 mg 1 times / day steady, oral
Recommended
Dose: 25 mg, 1 times / day
Route: oral
Route: steady
Dose: 25 mg, 1 times / day
Sources: Page: p. 48
unhealthy, adult
n = 6626
Health Status: unhealthy
Age Group: adult
Population Size: 6626
Sources: Page: p. 48
Blood creatinine increased 6 patients
Disc. AE
25 mg 1 times / day steady, oral
Recommended
Dose: 25 mg, 1 times / day
Route: oral
Route: steady
Dose: 25 mg, 1 times / day
Sources: Page: p. 48
unhealthy, adult
n = 6626
Health Status: unhealthy
Age Group: adult
Population Size: 6626
Sources: Page: p. 48
Acute myocardial infarction 8 patients
Disc. AE
25 mg 1 times / day steady, oral
Recommended
Dose: 25 mg, 1 times / day
Route: oral
Route: steady
Dose: 25 mg, 1 times / day
Sources: Page: p. 48
unhealthy, adult
n = 6626
Health Status: unhealthy
Age Group: adult
Population Size: 6626
Sources: Page: p. 48
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
little or no
little or no
little or no
little or no
no [IC50 78 uM]
no (co-administration study)
Comment: mechanism-based inhibition using midazolam; did not change in vivo 3A4 substrates (midazolam and atorvastatin exposure)
Page: 165.0
no
no
no
no
no
no
no
some [IC50 >100 uM]
weak (co-administration study)
Comment: increased dextromethorphan AUC by 26%
Page: 165.0
yes
no (co-administration study)
Comment: induction at 100 µM was 27.6% as effective as rifampin; did not affect exposure of 3A4 substrates (midazolam and atorvastatin)
Page: 166;62
Drug as victimTox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase IV.
2008
Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes.
2008 Dec
Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia.
2009 Dec
Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
2009 Feb
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy.
2009 Feb
Overview of the gliptin class (dipeptidyl peptidase-4 inhibitors) in clinical practice.
2009 Jan
Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study.
2009 Jan
The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice.
2009 Jan 14
A novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR-322), is effective in diabetic rats with sulfonylurea-induced secondary failure.
2009 Jul 17
A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease.
2009 Jul 20
Alogliptin: a new addition to the class of DPP-4 inhibitors.
2009 Jul 21
Incretin-based therapies: new treatments for type 2 diabetes in the new millennium.
2009 Jun
Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice.
2009 Jun
DPP4 inhibitors: from sitagliptin monotherapy to the new alogliptin-pioglitazone combination therapy.
2009 Mar
Diabetes treatment.
2009 Mar
Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes.
2009 Mar 1
Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice.
2009 May
Clinical pharmacology of alogliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of Type 2 diabetes.
2009 Nov
Incretin-based therapies: viewpoints on the way to consensus.
2009 Nov
Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies.
2009 Nov
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.
2009 Oct
Coadministration of pioglitazone or glyburide and alogliptin: pharmacokinetic drug interaction assessment in healthy participants.
2009 Oct
The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone.
2009 Sep
Efficacy and safety of incretin based therapies: clinical trial data.
2009 Sep-Oct
Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
2009 Sep-Oct
New therapeutic horizons: mapping the future of glycemic control with incretin-based therapy.
2009 Sep-Oct
Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy.
2010
Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat).
2010
Recommendations for management of diabetes during Ramadan: update 2010.
2010 Aug
Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.
2010 Aug
Managing type 2 diabetes in the primary care setting: beyond glucocentricity.
2010 Aug
Triple Combination Therapy Using Metformin, Thiazolidinedione, and a GLP-1 Analog or DPP-IV Inhibitor in Patients with Type 2 Diabetes Mellitus.
2010 Dec
Incretin concepts.
2010 Feb
The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes--a comprehensive review.
2010 Jan
Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects.
2010 Jan
The evolving place of incretin-based therapies in type 2 diabetes.
2010 Jul
Synthesis of a novel analogue of DPP-4 inhibitor Alogliptin: Introduction of a spirocyclic moiety on the piperidine ring.
2010 Jul 1
Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies.
2010 Jul 9
The physiologic role of incretin hormones: clinical applications.
2010 Mar
Combination treatment with alogliptin and voglibose increases active GLP-1 circulation, prevents the development of diabetes and preserves pancreatic beta-cells in prediabetic db/db mice.
2010 Mar
Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk.
2010 Mar 24
New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin.
2010 May 10
DPP-4 inhibitors: what may be the clinical differentiators?
2010 Nov
Treatment of elderly patients with type 2 diabetes mellitus: a systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors.
2010 Oct
Alogliptin: a review of its use in the management of type 2 diabetes mellitus.
2010 Oct 22
Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.
2010 Sep
Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment.
2010 Sep 7
Exenatide once weekly: clinical outcomes and patient satisfaction.
2010 Sep 7
Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors.
2012 Aug 1
Novel pyrrolopyrimidine analogues as potent dipeptidyl peptidase IV inhibitors based on pharmacokinetic property-driven optimization.
2012 Jun
Patents

Sample Use Guides

The recommended dose in patients with normal renal function or mild renal impairment is 25 mg once daily. Can be taken with or without food. Adjust dose if moderate or severe renal impairment or end-stage renal disease (ESRD).
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Sat Jun 26 09:49:32 UTC 2021
Edited
by admin
on Sat Jun 26 09:49:32 UTC 2021
Record UNII
EEN99869SC
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ALOGLIPTIN BENZOATE
JAN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
USAN  
Official Name English
ALOGLIPTIN BENZOATE [ORANGE BOOK]
Common Name English
ALOGLIPTIN BENZOATE [MI]
Common Name English
ALOGLIPTIN BENZOATE [USAN]
Common Name English
ALOGLIPTIN BENZOATE COMPONENT OF KAZANO
Brand Name English
SYR 322
Code English
2-((6-((3R)-3-AMINOPIPERIDIN-1-YL)-3-METHYL-2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1(2H)-YL)METHYL)BENZONITRILE MONOBENZOATE
Systematic Name English
ALOGLIPTIN BENZOATE [MART.]
Common Name English
ALOGLIPTIN BENZOATE [VANDF]
Common Name English
ALOGLIPTIN BENZOATE [JAN]
Common Name English
ALOGLIPTIN BENZOATE [WHO-DD]
Common Name English
OSENI COMPONENT ALOGLIPTIN BENZOATE
Brand Name English
ALOGLIPTIN BENZOATE COMPONENT OF OSENI
Brand Name English
ALOGLIPTIN (AS BENZOATE)
Common Name English
SYR-322
Code English
BENZONITRILE, 2-((6-((3R)-3-AMINO-1-PIPERIDINYL)-3,4-DIHYDRO-3-METHYL-2,4-DIOXO-1(2H)-PYRIMIDINYL)METHYL)-, MONOBENZOATE
Systematic Name English
KAZANO COMPONENT ALOGLIPTIN BENZOATE
Brand Name English
2-((6-((3R)-3-AMINO-1-PIPERIDINYL)-3,4-DIHYDRO-3-METHYL-2,4-DIOXO-1(2H)- PYRIMIDINYL)METHYL)BENZONITRILE MONOBENZOATE
Systematic Name English
NESINA
Brand Name English
Classification Tree Code System Code
NCI_THESAURUS C98086
Created by admin on Sat Jun 26 09:49:32 UTC 2021 , Edited by admin on Sat Jun 26 09:49:32 UTC 2021
Code System Code Type Description
DRUG BANK
DBSALT000007
Created by admin on Sat Jun 26 09:49:32 UTC 2021 , Edited by admin on Sat Jun 26 09:49:32 UTC 2021
PRIMARY
FDA UNII
EEN99869SC
Created by admin on Sat Jun 26 09:49:32 UTC 2021 , Edited by admin on Sat Jun 26 09:49:32 UTC 2021
PRIMARY
CAS
850649-62-6
Created by admin on Sat Jun 26 09:49:32 UTC 2021 , Edited by admin on Sat Jun 26 09:49:32 UTC 2021
PRIMARY
RXCUI
1368000
Created by admin on Sat Jun 26 09:49:32 UTC 2021 , Edited by admin on Sat Jun 26 09:49:32 UTC 2021
PRIMARY RxNorm
ChEMBL
CHEMBL376359
Created by admin on Sat Jun 26 09:49:32 UTC 2021 , Edited by admin on Sat Jun 26 09:49:32 UTC 2021
PRIMARY
MERCK INDEX
M1572
Created by admin on Sat Jun 26 09:49:32 UTC 2021 , Edited by admin on Sat Jun 26 09:49:32 UTC 2021
PRIMARY Merck Index
PUBCHEM
16088021
Created by admin on Sat Jun 26 09:49:32 UTC 2021 , Edited by admin on Sat Jun 26 09:49:32 UTC 2021
PRIMARY
NCI_THESAURUS
C75186
Created by admin on Sat Jun 26 09:49:32 UTC 2021 , Edited by admin on Sat Jun 26 09:49:32 UTC 2021
PRIMARY
EPA CompTox
850649-62-6
Created by admin on Sat Jun 26 09:49:32 UTC 2021 , Edited by admin on Sat Jun 26 09:49:32 UTC 2021
PRIMARY
EVMPD
SUB32165
Created by admin on Sat Jun 26 09:49:32 UTC 2021 , Edited by admin on Sat Jun 26 09:49:32 UTC 2021
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY